External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Thematic (Sector/Industry)

<ul><li>IRB Infra: IRB Infrastructure Developers Limited (IRB) reported revenue/EBITDA/APAT of INR 17.8/7.4/60bn, beat/(miss) to our estimates of 5.9/-4.24/159% respectively</li><li>The order book (OB) as of Dec’24 stood at INR 315bn, with EPC contributing 10% (INR 32bn) and O&amp;M contributing 90% (INR 283bn)</li><li>Moreover, in the long term, the company is expecting opportunities under the PPP mode for BOT projects worth INR 2trn</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

IRB Infra: IRB Infrastructure Developers Limited (IRB) reported revenue/EBITDA/APAT of INR 17.8/7.4/60bn, beat/(miss) to our estimates of 5.9/-4.24/159% respectivelyThe order book (OB) as of Dec’24 stood at INR 315bn, with EPC contributing 10% (INR 32bn) and O&amp;M contributing 90% (INR 283bn)Moreover, in the long term, the company is expecting opportunities under the PPP mode for BOT projects worth INR 2trnContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: IRB Infra, Relaxo Footwears

<ul><li>Larsen &amp; Toubro: Larsen &amp; Toubro (LT) reported revenue/EBITDA/APAT at INR 615.5/63.6/33.9bn, a beat/(miss) of 6.3/0.6/1.5%</li><li>P&amp;M margins came in at 7.6% (+20bps YoY), and LT expects to maintain a positive YoY margin expansion trend in ensuing quarters and retained 8.2-8.25% guidance for FY25</li><li>Despite Q2FY25 being impacted by heavy monsoon, LT reported strong 20.6% YoY revenue growth and maintained 15/10% revenue/order inflow guidance for FY25</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Larsen &amp; Toubro: Larsen &amp; Toubro (LT) reported revenue/EBITDA/APAT at INR 615.5/63.6/33.9bn, a beat/(miss) of 6.3/0.6/1.5%P&amp;M margins came in at 7.6% (+20bps YoY), and LT expects to maintain a positive YoY margin expansion trend in ensuing quarters and retained 8.2-8.25% guidance for FY25Despite Q2FY25 being impacted by heavy monsoon, LT reported strong 20.6% YoY revenue growth and maintained 15/10% revenue/order inflow guidance for FY25Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: Larsen & Toubro, Prestige Estates, Voltas, Kaynes Technology

<ul><li>Dr Reddy’s Laboratories: EBITDA grew (14% YoY) as +13% YoY sales growth (-3% QoQ US, +5% YoY in EU, +9% YoY EMs, and +34% YoY in RoW, India declined 12% YoY, adjusted growth was at 11%), steady gross margin (+65 bps YoY) and muted staff cost were offset by higher R&amp;D/SG&amp;A (+28/+22% YoY)</li><li>DRRD expects to sustain growth in the US over the next few years with steady traction in gRevlimid and new launches (20+ launches p.a for the next few years)</li><li>The company expects India to see steady growth in FY25, led by new launches, scale-up in key therapies, and in-licensing opportunities</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dr Reddy’s Laboratories: EBITDA grew (14% YoY) as +13% YoY sales growth (-3% QoQ US, +5% YoY in EU, +9% YoY EMs, and +34% YoY in RoW, India declined 12% YoY, adjusted growth was at 11%), steady gross margin (+65 bps YoY) and muted staff cost were offset by higher R&amp;D/SG&amp;A (+28/+22% YoY)DRRD expects to sustain growth in the US over the next few years with steady traction in gRevlimid and new launches (20+ launches p.a for the next few years)The company expects India to see steady growth in FY25, led by new launches, scale-up in key therapies, and in-licensing opportunitiesContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: Dr Reddy’s Laboratories, Lupin, IRB Infra, Max Financial

<ul><li>Titan: Titan’s top line grew 22% YoY to INR 141.6bn (HSIE: INR 148.2bn)</li><li>Jewellery (ex-bullion) sales grew 24% YoY to INR125.6bn (in-line)</li><li>Festive purchases resulted in double-digit buyer growth in jewellery, moderation was seen after Nov-23 though Consolidated EBITDAM contracted 55 bps YoY to 11% (in-line)</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Titan: Titan’s top line grew 22% YoY to INR 141.6bn (HSIE: INR 148.2bn)Jewellery (ex-bullion) sales grew 24% YoY to INR125.6bn (in-line)Festive purchases resulted in double-digit buyer growth in jewellery, moderation was seen after Nov-23 though Consolidated EBITDAM contracted 55 bps YoY to 11% (in-line)Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: Titan, Astral, Aditya Birla Capital, IRB Infra

<ul><li>TVS Motor: TVS Motors’ Q2 PAT at INR 5.4bn came in line with our estimates</li><li>The highlight for Q2 was the record-high 11% margin despite the ramp-up of i-Qube to 58k units</li><li>While TVS gained about 300bps market share in motorcycles in H1 to 10.3%, it has maintained its share in scooters</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

TVS Motor: TVS Motors’ Q2 PAT at INR 5.4bn came in line with our estimatesThe highlight for Q2 was the record-high 11% margin despite the ramp-up of i-Qube to 58k unitsWhile TVS gained about 300bps market share in motorcycles in H1 to 10.3%, it has maintained its share in scootersContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: TVS Motor, Macrotech Developers, Marico

India

IRB Infrastructure Developers is an Indian highway construction company specializing in the development and operation of highways and expressways through Build-Operate-Transfer (BOT), Toll-Operate-Transfer (TOT), and Hybrid Annuity Model (HAM) frameworks. It also invests in units of IRB Infrastructure Trust and IRB InvIT Fund, and has interests in real estate, hospitality, and airport development. The company was founded in 1998 and is headquartered in Mumbai, India.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

IRB Infrastructure Developers (IRB IN)

HSIE Results Daily: IRB Infra, Relaxo Footwears

IRB Infrastructure Developers Limited (IRB) reported revenue/EBITDA/APAT of INR 17.8/7.4/60bn, beat/(miss) to our estimates of 5.9/-4.24/159%...

HDFC Securities

HSIE Results Daily: Larsen & Toubro, Prestige Estates, Voltas, Kaynes Technology

Larsen & Toubro: Larsen & Toubro (LT) reported revenue/EBITDA/APAT at INR 615.5/63.6/33.9bn, a beat/(miss) of 6.3/0.6/1.5%

HDFC Securities

HSIE Results Daily: Dr Reddy’s Laboratories, Lupin, IRB Infra, Max Financial

DRRD expects to sustain growth in the US over the next few years with steady traction in gRevlimid and new launches (20+ launches p.a for the next...

HDFC Securities

HSIE Results Daily: Titan, Astral, Aditya Birla Capital, IRB Infra

Festive purchases resulted in double-digit buyer growth in jewellery, moderation was seen after Nov-23 though Consolidated EBITDAM contracted 55...

HDFC Securities

HSIE Results Daily: TVS Motor, Macrotech Developers, Marico

TVS Motor: TVS Motors’ Q2 PAT at INR 5.4bn came in line with our estimates. The highlight for Q2 was the record-high 11% margin despite the ramp-up...

HDFC Securities

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)